外周血单个核细胞内乙型肝炎病毒DNA评估拉米夫定治疗慢性乙型肝炎预后的研究  

HBV DNA in PBMC as predictor of response to Lamifudin therapy in chronic hepatitis B

作　　者：太永日[1] 朴红心[1] 尹明实 韩学吉[1] 崔鹤松[1] 

机构地区：[1]延边大学医院感染症科,吉林延吉133000

出　　处：《中国现代医学杂志》2007年第18期2237-2239,共3页China Journal of Modern Medicine

摘　　要：目的探讨拉米夫定治疗慢性乙型肝炎结束时,外周血单个核细胞(PBMC)中HBV DNA检测对持续性应答的预测作用。方法对100例慢性乙型肝炎患者进行拉米夫定治疗96周,选择完全应答的80例病人,检测PBMC中HBV DNA,并对患者进行长期的血清HBV DNA监测。结果治疗结束时,有68例患者的PBMC HBV DNA为阳性,12例为阴性。在PBMC中HBV DNA阳性患者,停止治疗的6个月内所有患者的HBV DNA复发。而PBMC HBV DNA阴性者,随访至停药1年,12例中仅2例HBV DNA阳转,其余10例,随访至3.5年,血清中HBV DNA仍阴性。结论拉米夫定治疗结束时PBCMC中HBV DNA检测能预测慢性乙型肝炎的治疗效果。[Objective] To investigate the predictive value of HBV DNA in PBMC of patients with chronic hepatitis B to 3TC treatment. [Methods] The HBV DNAs in PBMC were detected at the end of treatment, and 96 week follow up after end treatment, in 80 patients who acquired complete response to 3TC in 96 weeks therapy. [Results] 68patints were HBV DNA positive in their PBMC at the end of treatment, and the serum HBV DNA of 68 showed positive after 24 weeks follow-up. In 12 patients with negative HBV DNA in PBMC, only 2 patients relapsed in serum HBV DNA after 1 year follow-up, and others remained viral response after 3.5 years. [Conclusion] HBV DNA in PBMC at the end of the treatment was a predictor of the durable response to antiviral therapy in chronic hepatitis B.

关 键 词：乙型肝炎 HBV DNA 拉米夫定 外周血单个核细胞 

分 类 号：R575.1[医药卫生—消化系统]